Ceftriaxone PharmSol 2 g Powder for Solution for Infusion

Country: Malta

Language: English

Source: Medicines Authority

Buy It Now

Active ingredient:

CEFTRIAXONE SODIUM

Available from:

PharmSol Europe Limited The Victoria Centre Unit 2, Lower Ground Floor, Valletta Road, Mosta MST 9012 , Malta

ATC code:

J01DD04

INN (International Name):

CEFTRIAXONE SODIUM

Pharmaceutical form:

POWDER FOR SOLUTION FOR INFUSION

Composition:

CEFTRIAXONE SODIUM 2 gram(s)

Prescription type:

POM

Therapeutic area:

ANTIBACTERIALS FOR SYSTEMIC USE

Product summary:

Licence number in the source country: NOT APPLICAPABLE

Authorization status:

Authorised

Authorization date:

2020-11-05

Patient Information leaflet

                                Page
1
of
11
PACKAGE LEAFLET: INFORMATION FOR THE USER
CEFTRIAXONE PHARMSOL 2 G POWDER FOR SOLUTION FOR INFUSION
_Ceftriaxone _
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
−
Keep this leaflet. You may need to read it again.
−
If you have any further questions, ask your doctor, pharmacist or
nurse.
−
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
−
If you get any side effects, talk to your doctor, pharmacist or
nurse.This includes any
possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ceftriaxone PharmSol is and what it is used for
2.
What you need to know before you are given Ceftriaxone PharmSol
3.
How Ceftriaxone PharmSol is given
4.
Possible side effects
5.
How to store Ceftriaxone PharmSol
6.
Contents of the pack and other information
1.
WHAT CEFTRIAXONE PHARMSOL IS AND WHAT IT IS USED FOR
Ceftriaxone PharmSol contains the active substance ceftriaxone which
is an antibiotic given to
adults and children (including newborn babies). It works by killing
bacteria that cause
infections. It belongs to a group of medicines called cephalosporins
_. _
Ceftriaxone PharmSol is used to treat infections of:
−
the brain (meningitis);
−
the lungs;
−
the abdomen and abdominal wall (peritonitis);
−
the urinary tract and kidneys;
−
bones and joints;
−
the skin or soft tissues;
−
the blood;
−
the heart.
Ceftriaxone PharmSol can be given:
−
to treat specific sexually transmitted infections (syphilis);
−
to treat patients with low white blood cell counts (neutropenia) who
have fever due to
bacterial infection;
−
to treat infections of the chest in adults with chronic bronchitis;
−
to treat Lyme disease (caused by tick bites) in adults and children
including newborn
babies from 15 days of age;
−
to prevent infections during surgery.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIV
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Page
1
of
17
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Ceftriaxone PharmSol 2 g Powder for Solution for Infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 2 g of ceftriaxone (as ceftriaxone sodium).
Excipient with known effect:
This medicinal product contains approximately 166 mg (7.2 mmol) of
sodium per 2 grams of
ceftriaxone.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for infusion.
An almost white or yellowish crystalline powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ceftriaxone PharmSol is indicated for the treatment of the following
infections in adults and
children including term neonates (from birth):
−
bacterial meningitis;
−
community acquired pneumonia;
−
hospital acquired pneumonia;
−
intra-abdominal infections;
−
complicated urinary tract infections (including pyelonephritis);
−
infections of bones and joints;
−
complicated skin and soft tissue infections;
−
syphilis;
−
bacterial endocarditis.
Ceftriaxone PharmSol may be used:
−
for treatment of acute exacerbations of chronic obstructive pulmonary
disease in adults;
−
for treatment of disseminated Lyme borreliosis (early (stage II) and
late (stage III)) in
adults and children including neonates from 15 days of age;
−
for pre-operative prophylaxis of surgical site infections;
−
in the management of neutropenic patients with fever that is suspected
to be due to a
bacterial infection;
−
in the treatment of patients with bacteraemia that occurs in
association with, or is
suspected to be associated with, any of the infections listed above.
Ceftriaxone PharmSol should be co-administered with other
antibacterial agents whenever the
possible range of causative bacteria would not fall within its
spectrum (see section 4.4).
Page
2
of
17
Consideration should be given to official guidelines on the
appropriate use of antibacterial
agents.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The dose depends on the severity, suscep
                                
                                Read the complete document
                                
                            

Search alerts related to this product